Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258940 | 0.91 | PTGIR (0.35) | PTGIR | |
| SCHEMBL21258972 | 0.90 | CHRM4 (0.34) | CHRM4NR1H4MMP2MCHR1LIPE | |
| SCHEMBL21258676 | 0.90 | PTGIR (0.38) | PTGIRLIPE | |
| SCHEMBL21258828 | 0.89 | PTGIR (0.37) | PTGIR | |
| SCHEMBL21258693 | 0.88 | PTGDR (0.33) | PTGIRFFAR4 | |
| SCHEMBL21258877 | 0.88 | PTGIR (0.37) | PTGIRNR1H4 | |
| SCHEMBL23655437 | 0.88 | PTGIR (0.32) | PTGIRNR1H4MMP2MCHR1PPARD | |
| SCHEMBL21258966 | 0.84 | PTGIR (0.40) | PTGIR | |
| SCHEMBL21258899 | 0.84 | PTGIR (0.39) | PTGIRFFAR4 | |
| SCHEMBL21258855 | 0.84 | PTGIR (0.49) | PTGIRCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338665-A1 | MEDICAL USE OF PROSTACYCLIN RECEPTOR AGONIST | CHINESE PLA GENERAL HOSPITAL (CN) | 2021-11-04 | — | — | US | disclosed |
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3750879-A1 | PROSTACYCLIN RECEPTOR AGONIST | Medshine Discovery Inc. (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154363-A1 | PROSTACYCLIN RECEPTOR AGONIST | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | PTGIR, TBXA2R, PTGFR | PTGIR 1/4885CHRM4 1406/4885NR1H4 171/4885 |
| US-20210338665-A1 | MEDICAL USE OF PROSTACYCLIN RECEPTOR AGONIST | PTGIR, CYP11B2, PDE8A | PTGIR 1/4885CHRM4 1046/4885NR1H4 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.